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The switch from the latent to the lytic form of Epstein-Barr virus (EBV) infection is mediated by expression
of the viral immediate-early (IE) proteins, BZLF1 (Z) and BRLF1 (R). An EBV early protein, BRRF1 (Na), is
encoded by the opposite strand of the BRLF1 intron, but the function of this nuclear protein in the viral life
cycle is unknown. Here we demonstrate that Na enhances the R-mediated induction of lytic EBV infection in
293 cells latently infected with a recombinant EBV (R-KO) defective for the expression of both R and Na. Na
also enhances R-induced lytic infections in a gastric carcinoma line (AGS) carrying the R-KO virus, although
it has no effect in a Burkitt lymphoma line (BL-30) stably infected with the same mutant virus. We show that
Na is a transcription factor that increases the ability of R to activate Z expression from the R-KO viral genome
in 293 cells and that Na by itself activates the Z promoter (Zp) in EBV-negative cells. Na activation of Zp
requires a CRE motif (ZII), and a consensus CRE motif is sufficient to transfer Na responsiveness to the
heterologous E1b promoter. Furthermore, we show that Na enhances the transactivator function of a Gal4–
c-Jun fusion protein but does not increase the transactivator function of other transcription factors (including
ATF-1, ATF-2, and CREB) known to bind CRE motifs. Na expression in cells results in increased levels of a
hyperphosphorylated form of c-Jun, suggesting a mechanism by which Na activates c-Jun. Our results indicate
that Na is a transcription factor that activates the EBV Zp IE promoter through its effects on c-Jun and suggest
that Na cooperates with BRLF1 to induce the lytic form of EBV infection in certain cell types.
Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus
typically acquired early in life through salivary exchange. EBV
is the causative agent of infectious mononucleosis and is asso-
ciated with a variety of malignancies of B-cell and epithelial
cell origin (48, 49). Like all herpesviruses, EBV can exist in
either a latent or lytic state with respect to viral gene expres-
sion. An infection of B cells typically results in latency, in which
only a subset of viral genes is expressed and progeny virus is
not released. Latently infected B cells occasionally reactivate
into the lytic cycle in response to stimuli such as B-cell activa-
tion (57) or differentiation (9). Differentiated epithelial cells
are also permissive for lytic infection (28, 32, 55, 65). The
induction of the viral lytic cycle in either B cells or epithelial
cells results in the expression of the majority of viral genes and
the release of progeny virus capable of infecting new cells.
Entry into the viral lytic cycle is initiated by expression of the
immediate-early (IE) EBV proteins, BZLF1 (Z) and BRLF1
(R) (7, 8, 45, 50, 58, 68). Z, a bZIP protein with sequence
homology to c-Jun and c-Fos, binds and transactivates promot-
ers containing AP-1-like motifs (6, 13, 59, 61). R can also
activate target promoters through direct binding (20, 21, 44);
however, R also activates transcription indirectly through the
induction of signaling cascades (1, 10). Stimuli that induce a
lytic infection initially activate the transcription of both IE
genes (57), and the expression of either IE protein in latently
infected cells is sufficient to induce the lytic form of EBV
infection (7, 8, 45, 58, 64, 68). Each IE protein activates the
promoter of the other IE gene, and together the two IE pro-
teins then activate the viral early genes and lytic viral replica-
tion (2, 14).
The ability of each IE protein to activate transcription of the
other IE gene is essential for the disruption of viral latency by
either protein (2, 14, 46, 68). Z transactivates the R promoter
(Rp) by directly binding to Rp (2, 54). In contrast, R activates
Z transcription by enhancing the transcriptional functions of
cellular factors (ATF-2 and c-Jun) binding to a CREB re-
sponse element (CRE) motif (ZII) in the Z promoter (Zp) (1).
This effect is mediated through the induction of the stress-
associated mitogen-activated protein (MAP) kinases (SAPKs)
p38 and c-Jun N-terminal kinase (JNK) (1), which phosphor-
ylate and activate the transcription factors ATF-2 and c-Jun,
respectively (12, 23, 47, 62).
In addition to the Z and R genes, the IE locus of EBV
contains another open reading frame, BRRF1 (also designated
Na), which lies within the first intron of the R gene and is
oriented in the opposite direction (38). Na mRNA appears
with early kinetics following induction of the viral lytic cycle in
several latently infected B-cell lines (38, 53). The promoter
driving expression of Na (Nap) is located within the coding
sequence for R, and reporter assays indicate that Nap is acti-
vated by Z (53). This activation may be mediated by the direct
binding of Z to Nap, given that Z binds several sites in Nap
between nucleotides 469 and 1 in electromobility shift as-
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says (53). The Na gene product is a 34-kDa protein that local-
izes to the nucleus in HeLa cells (53). However, no studies to
date have identified a function for Na.
For this paper, we examined the role of Na in the viral life
cycle. Utilizing several different cell lines that are latently in-
fected with a recombinant EBV defective for expression of
both R and Na, we demonstrate that the Na gene product
cooperates with R to induce an efficient lytic EBV infection in
certain cell lines. Furthermore, we show that Na by itself ac-
tivates promoters containing CRE motifs (including the IE Z
promoter) in EBV-negative cell lines and that this effect is
mediated through an enhanced c-Jun transcriptional function.
However, Na by itself cannot activate BZLF1 transcription in
the context of the intact viral genome. Our results suggest the
existence of a previously unexpected positive auto-regulatory
circuit for R-mediated lytic EBV induction, in which R by itself
initially activates BZLF1 transcription with a low efficiency, but
subsequently activates BZLF1 transcription with a much
higher efficiency (in conjunction with Na) after the Z gene
product has induced Na transcription.
MATERIALS AND METHODS
Plasmids. The Na expression vector pRC-FLAG-BRRF1 and the Z expres-
sion vector pSG5-Z were described previously (51, 53). pSG5-R (a gift from
Diane Hayward) contains the genomic R sequence beginning with the second
exon (including the ATG start codon for R) but lacking the first intron (con-
taining the Na gene) (24). Appropriate control vectors, pRC (Invitrogen) and
pSG5 (Stratagene), were used in all experiments. The pRK5-BALF4 expression
vector encodes the EBV gp110 protein and was previously shown to enhance the
infection efficiency of EBV virions derived from the B95-8 strain of EBV (42).
Zp-CAT, Zp-CAT ZIA/ZIB, Zp-CAT ZII, and 65Zp-CAT (all gifts from E.
Flemington) were described previously (17). Briefly, Zp-CAT contains the region
of the BZLF1 promoter from 221 to 12 (relative to the transcription start
site) linked upstream of the chloramphenicol acetyltransferase (CAT) gene.
Zp-CAT ZIA/ZIB and Zp-CAT ZII represent mutants of Zp in which the
ZIA and ZIB sites and the ZII site, respectively, have been mutated via site-
directed mutagenesis. The plasmid 65Zp-CAT contains nucleotides 65 to
12 of Zp upstream of CAT. EApBS-CAT (also called BMRF1-CAT) contains
the BMRF1 promoter sequence from 331 to 1 upstream of CAT and was
described previously (44). CRE-CAT contains three consensus CRE sites up-
stream of CAT; CRE(m)-CAT is identical to CRE-CAT except for specific
mutations in the CRE site. The SG424 vector encodes the Gal4 DNA binding
domain alone, whereas Gal4-CREB, Gal4-ATF1, Gal4-ATF2 (all gifts from M.
Green), and Gal4–c-Jun (a gift from A. Baldwin) contain the respective proteins
linked in-frame to the Gal4 DNA binding domain. Gal4-EIB-CAT (a gift from
M. Green) consists of five copies of the Gal4 DNA binding site linked upstream
of the minimal EIB TATA box and CAT gene. The CR2/puro expression vector
was a gift from L. Hutt-Fletcher; CR2 is the primary cellular receptor for EBV
(15). CMV–c-Jun expresses full-length c-Jun under the control of the cytomeg-
alovirus (CMV) promoter. Plasmids were purified by use of Qiagen Maxiprep
kits (Qiagen) according to the manufacturer’s instructions.
EBV wild-type, Z-KO, and R-KO viruses and cell lines. 293 cells infected with
the R-KO virus (293 R-KO), Z-KO virus (293 Z-KO), and wild-type virus (293
WT) have been described previously (11, 14). In the R-KO virus, nucleotides
103,638 to 105,083 (B95.8 coordinates [accession no. V01555]) within the BRLF1
gene were removed via the insertion of a tetracycline resistance cassette into the
virus (14). In the Z-KO virus, nucleotides 102,389 to 103,388 (B95.8 coordinates)
within the BZLF1 gene were removed via the insertion of a kanamycin resistance
cassette. The R-KO, Z-KO, and WT viruses also encode enhanced green fluo-
rescent protein (GFP) and a hygromycin B resistance gene (both cloned into the
B95.8 deletion of EBV, where the second copy of oriLyt normally resides). 293
R-KO, 293 Z-KO, and 293 WT cells were maintained in Dulbecco’s modified
Eagle medium containing 10% fetal bovine serum (FBS), penicillin-streptomy-
cin, and hygromycin B (100 g/ml; Roche). HeLa cells are a cervical adenocar-
cinoma line and were maintained in Dulbecco’s modified Eagle medium with
10% FBS and penicillin-streptomycin. AGS R-KO cells (see below) were main-
tained in F-12 medium containing 10% FBS, penicillin-streptomycin, and 100 g
of hygromycin B/ml. BL30 R-KO cells and LCL R-KO cells (see below) were
maintained in RPMI 1640 medium supplemented with 10% FBS, penicillin-
streptomycin, and 400 g of hygromycin B/ml. Raji cells, an EBV-positive Bur-
kitt lymphoma cell line, were maintained in RPMI 1640 with 10% FBS and
penicillin-streptomycin.
DNA transfection. Transfections of 293 R-KO and 293 WT cells were done by
use of Lipofectamine 2000 (Invitrogen). Cells (6  105) were seeded the day
prior to transfection in 2 ml of medium in a six-well plate. Transfections were
performed according to the manufacturer’s instructions, except that the reagent/
DNA ratio was scaled down to 2 l/1 g. Transfections of HeLa cells for reporter
assays were performed by use of Fugene 6 (Roche) according to the manufac-
turer’s instructions. AGS R-KO cells were electroporated with 5 g of total DNA
in a Zapper electroporation unit as described previously (60). BL30 R-KO and
LCL R-KO cells were transfected in buffer V (Amaxa Biosystems) with an
Amaxa Nucleofector (Amaxa Biosystems). Cells were cultured for 24 h in anti-
biotic-free medium, followed by two washes in 1 phosphate-buffered saline
(PBS). Cells (107) were resuspended in 100 l of buffer V (per condition) and 5
g of total DNA was added. Settings G-16 and T-20 were used for BL30 R-KO
and LCL R-KO cells, respectively. After being transfected, cells were incubated
overnight in 1.5 ml of antibiotic-free medium at 37°C in a 12-well plate; 2.5 ml of
complete medium was then added.
Generation of R-KO cell lines. For the production of R-KO viral stocks, 5 
106 293 R-KO cells were plated in 10 ml of RPMI 1640–10% FBS–penicillin-
streptomycin in a 100-mm-diameter dish the day prior to transfection. The cells
were transfected with 1.5 g each of pSG5-R, pSG5-Z, pRC-FLAG-BRRF1, and
pRK5-BALF4 expression plasmids by use of Lipofectamine 2000 (12 l of
reagent per condition) according to the manufacturer’s instructions. At 72 h
posttransfection, supernatants were filtered through 0.45-m-pore-size filters
and viral stocks were stored at 4°C. AGS cells (a gift from L. Hutt-Fletcher) are
an EBV-negative gastric adenocarcinoma cell line. In order to create an AGS
line infected with the R-KO virus, we first transfected AGS cells with 1 g of an
expression vector encoding CD21-puromycin resistance by using Fugene 6
(Roche) according to the manufacturer’s instructions. At 48 h posttransfection,
cells were selected with 0.5 g of puromycin HCl (Roche)/ml; puromycin-resis-
tant colonies were pooled. For infections with R-KO virus, puromycin-resistant
cells were seeded at 50% confluence in a 60-mm-diameter dish and were incu-
bated with R-KO viral stocks. Four days after infection, cells were selected with
hygromycin B (100 g/ml); one hygromycin B-resistant colony representing an
AGS cell infected with the R-KO virus was isolated. BL30 cells are an EBV-
negative Burkitt lymphoma line. For the generation of BL30 R-KO cells, ap-
proximately 5  106 BL30 cells were pelleted and resuspended in 5 ml of R-KO
viral stock for 3 h at 37°C. After the incubation, the cells were diluted into 50 ml
of medium. Selection with 400 g of hygromycin B/ml was begun at 5 days
postinfection. For the generation of LCL R-KO cells, 3  106 peripheral blood
mononuclear cells (provided by the laboratory of Susan Fiscus, University of
North Carolina at Chapel Hill) were resuspended in 3 ml of R-KO virus and
incubated overnight at 37°C. Seven milliliters of RPMI 1640–20% FBS–penicil-
lin-streptomycin was then added, and cyclosporine A (Sigma) was added to
achieve a final concentration of 500 ng/ml. Fifty percent of the medium was
changed every 7 days until transformation into LCLs was apparent (at 3 to 4
weeks postinfection). LCLs were then maintained in RPMI 1640–10% FBS–
penicillin-streptomycin.
Northern blotting. Total RNAs were prepared by use of RNAeasy kits (Qia-
gen), including DNase treatment, according to the manufacturer’s instructions.
Ten micrograms of total RNA was subjected to denaturing agarose gel electro-
phoresis, and fractionated RNAs were transferred to a membrane by use of the
Turboblotter system (Schleicher and Schuell) according to the manufacturer’s
instructions. After being transferred, RNAs were cross-linked to the membrane
via UV irradiation (1,200 J). The following double-stranded DNA fragments
were used as probes for Z, Na, and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), respectively: a PstI/HindIII fragment from pSG5-Z, a BglII/XhoI
fragment of pRC-FLAG-BRRF1, and a mouse GAPDH DECAtemplate (Am-
bion). Double-stranded DNA fragments were gel purified with a Qiagen gel
extraction kit (Qiagen) and radiolabeled with a Prime-A-Gene kit (Promega),
and unincorporated radioactivity was removed by the use of Sephadex G-50
columns (Amersham); all steps were performed according to the manufacturer’s
instructions. Prehybridization and hybridization (2  106 cpm of probe) were
performed in Quikhyb solution (Stratagene) according to the manufacturer’s
instructions. Membranes were exposed to film overnight at 80°C.
Immunoblotting. Immunoblotting was performed as described previously (1).
Briefly, cells were lysed in NP-40 lysis buffer supplemented with protease and
phosphatase inhibitors; equivalent amounts of protein were then separated in
sodium dodecyl sulfate–10% polyacrylamide gel electrophoresis gels. For the
examination of c-Jun phosphorylation status, cells were kept at 4°C at all times
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during the harvesting procedure. After being transferred and blocked, mem-
branes were incubated overnight at 4°C with the appropriate primary antibodies
diluted in 5% milk in 1 PBS and 0.1% Tween 20 (PBS-T). Primary antibody
dilutions were as follows: 1:100 anti-BRLF1 (Argene), 1:100 anti-BZLF1 (Ar-
gene), 1:100 anti-BMRF1 (Capricorn), 1 g of M2 anti-FLAG (Sigma)/ml, and
1:5,000 anti--actin (clone AC-15; Sigma). Anti-c-Jun (Cell Signaling) and anti-
phosphoSer73-c-Jun (Cell Signaling) antibodies were diluted 1:1,000 in 5% bo-
vine serum albumin in 1 PBS-T. The appropriate horseradish peroxidase-
conjugated secondary antibodies (Promega) were used at a dilution of 1:10,000
in 5% milk–1 PBS-T for 1 h at room temperature. After being washed, bound
antibodies were visualized by use of ECL reagent (Amersham) according to the
manufacturer’s instructions.
CAT assays. CAT assays were performed as described previously (19) with cell
extracts harvested at 48 h posttransfection. Chloramphenicol acetylation was
determined by thin-layer chromatography followed by PhosphorImager (Molec-
ular Dynamics) quantification.
Viral titration assay. Supernatants from 293 R-KO cells were harvested at 48 h
posttransfection and filtered through a 0.45-m-pore-size filter. Raji cells (2 
105) were then incubated in 0.5 ml of virus for 3 h at 37°C in a 12-well plate. One
and one-half milliliters of medium was then added to each well and the cells were
incubated for an additional 48 h at 37°C. Phorbol-12-myristate-3-acetate (PMA;
Sigma) and sodium butyrate (Sigma) were then added to achieve a final concen-
tration of 50 ng of PMA/ml and 3 mM sodium butyrate. The number of GFP-
expressing Raji cells was quantitated 24 h later by fluorescence microscopy.
RESULTS
293 R-KO cells cannot express Na. The phenotype of a
recombinant EBV in which the majority of the R gene has
been disrupted through insertional mutagenesis (293 R-KO)
(Fig. 1) was previously described for 293 cells as well as pri-
mary B cells immortalized by this virus (14). The R-KO virus is
similar to the wild-type virus in terms of its ability to immor-
talize primary B cells, but 293 cells carrying the R-KO virus
could not be induced into the lytic form of EBV infection
unless a vector expressing the BRLF1 gene product was sup-
plied in trans (14). These results were interpreted as showing
that the lytic defect of the R-KO virus is completely rescued by
the BRLF1 IE protein in trans (14).
Notably, however, the EBV sequences deleted from the
R-KO virus (nucleotides 103,638 to 105,083 in the B95.8 strain
coordinates) not only include the BRLF1 gene, but simulta-
neously include essentially all of the Na promoter, except for
the sequences located within 36 bp of the Na transcriptional
start site (Fig. 1). Thus, we hypothesized that the R-KO virus
cannot efficiently transcribe the Na message. Furthermore,
since the BRLF1 expression vector which was previously used
to rescue the lytic defect of the R-KO virus in 293 cells also
contained the EBV sequences encoding the Na gene product
as well as the Na promoter (14), this vector could potentially
express both BRLF1 and Na.
To determine if the R-KO virus is indeed defective for Na
expression, we performed a Northern blot analysis of total
RNAs from 293 WT, 293 Z-KO, and 293 R-KO cells trans-
fected with an empty vector, a vector expressing Z (which
induces the expression of Na [53]), and a vector expressing R
that does not contain the intronic sequence in which the Na
gene lies. As shown in Fig. 2, as expected, the expression of
either Z or R in the 293 WT line induced transcription of the
1.3-kb Na message. R induction of the BZLF1 message, as well
as Z induction of the BRLF1 message, in the 293 WT line
could be detected upon a longer exposure (data not shown). In
the 293 Z-KO line, Z induced the transcription of Na, whereas
R did not, indicating that R cannot induce Na expression
without the help of Z. In 293 R-KO cells, neither Z nor R
expression induced the transcription of Na, confirming that 293
cells infected with the R-KO virus cannot transcribe Na under
the conditions in which it is normally expressed. Thus, 293
R-KO cells provide an environment to study the effects of Na
during the viral life cycle.
Expression of Na enhances the capacity of R to efficiently
induce lytic infection in 293 R-KO cells. To determine if Na
affects the ability of R to induce a lytic EBV infection in 293
R-KO cells, we transfected these cells with a vector control, a
FIG. 1. Diagram of the IE region of the EBV genome. The IE
locus of EBV is depicted, with the positions of the BZLF1, BRLF1,
BRRF1 (Na), and RAZ genes indicated. Promoters for BZLF1 (Zp),
BRLF1 (Rp), and BRRF1 (Nap) are designated by arrows. Transcripts
originating from each of the various promoters are depicted, and the
proteins encoded (Z, R, RAZ, or Na) by each transcript are indicated
above their respective mRNAs. The insertional mutations carried by
the Z-KO virus and the R-KO virus are indicated by the gray boxes in
the bottom diagram; numbers represent coordinates of the EBV strain
B95.8 genome (accession no. V01555).
FIG. 2. 293 R-KO cells cannot transcribe BRRF1 mRNA. 293 WT,
293 Z-KO, or 293 R-KO cells were transfected with pSG5 (vector),
pSG5-Z (Z), or pSG5-R (R). At 24 h posttransfection, total RNAs
were harvested and Northern blotted as described in Materials and
Methods. Membranes were hybridized with probes specific for BRRF1
(Na), R, Z, and GAPDH transcripts, as indicated by arrows.
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vector that expresses Na (FLAG-tagged), a vector that ex-
presses R but not Na, or a combination of the R and Na
vectors. The efficiency of early lytic gene induction was as-
sessed by quantitating the expression of IE and early lytic
proteins 48 h after transfection. As shown in Fig. 3A, the R
vector alone induced only a low-level expression of the early
BMRF1 protein in 293 R-KO cells, whereas 293 WT cells
transfected with the R vector expressed considerably more
BMRF1. Furthermore, although Na alone did not activate Z or
BMRF1 expression in 293 R-KO cells, the combination of Na
and R was much more effective than R alone in inducing both
Z and BMRF1 expression (Fig. 3B).
As shown in Fig. 1, the R-KO deletion also removes a por-
tion of the R-derived N terminus of RAZ (Fig. 1) as well as the
first RAZ splice site, suggesting that the R-KO virus cannot
express RAZ. RAZ is a chimeric protein consisting of the N
terminus of R fused to the C terminus of Z that may function
to repress Z activity (18, 52). To determine whether the ab-
sence of RAZ expression in 293 R-KO cells had an impact on
the lytic infection induced by R, we transfected 293 R-KO cells
with R alone, R and RAZ, R and Na, or R, Na, and RAZ in
combination. The transfection of RAZ did not enhance the
capacity of R alone or R in conjunction with Na to induce
BMRF1 expression (data not shown). Thus, the inability of R
to efficiently activate early lytic gene transcription in 293 R-KO
cells likely reflects the loss of the Na, rather than RAZ, func-
tion in the mutant R-KO virus.
FIG. 3. Na enhances R-induced lytic infection in 293 R-KO cells.
(A) 293 R-KO or 293 WT cells were transfected with pSG5 (vector) or
pSG5-R (R). Cells were harvested at 48 h posttransfection, and 35 g
of protein was immunoblotted with antibodies specific for the early
lytic protein BMRF1 (upper panel) or R (lower panel). (B) 293 R-KO
cells were transfected with pSG5 (vector), pRC-FLAG-BRRF1 (Na),
pSG5-R (R), or pRC-FLAG-BRRF1 and pSG5-R (NaR). Cells were
harvested at 48 h posttransfection, and 35 g of protein was immuno-
blotted with antibodies specific for BMRF1, Z, R, FLAG (to detect
FLAG-tagged Na), and -actin, as indicated by arrows.
FIG. 4. Na enhances R-induced lytic infection in a cell-line-depen-
dent manner. AGS R-KO (A), BL30 R-KO (B), or LCL R-KO (C)
cells were transfected with pRC (vector), pRC-FLAG-BRRF1 (Na),
pSG5-R (R), or pRC-FLAG-BRRF1 and pSG5-R (NaR). Cells were
harvested at 48 h posttransfection, and 35 g of protein was immuno-
blotted with the indicated antibodies. Densitometric analysis was per-
formed with NIH Image software. AGS(), EBV-negative AGS cells.
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Na enhances R-induced lytic infection in a cell-line-depen-
dent manner. To determine if the ability of Na to enhance
R-induced lytic infection is a universal phenomenon among
various cell lines, we derived several other cell lines containing
the R-KO virus, including a gastric carcinoma line (AGS
R-KO), a lymphoblastoid cell line (LCL R-KO), and a Burkitt
lymphoma line (BL30 R-KO), and examined whether the abil-
ity of transfected R to induce early viral gene expression was
likewise enhanced by Na expression (Fig. 4). The results indi-
cated that the synergy between Na and R in inducing BMRF1
expression is cell line dependent. AGS cells infected with wild-
type EBV have a relatively high proportion of lytically infected
cells (39). Interestingly, AGS cells infected with the R-KO
virus demonstrated the expression of Z even in the absence of
R (Fig. 4A), suggesting that cellular factors are sufficient to
activate Z transcription in this cell line. Nevertheless, the abil-
ity of transfected R to induce BMRF1 transcription was en-
hanced 2.2-fold by the presence of Na in AGS R-KO cells (Fig.
4A). In contrast, in the BL30 R-KO line, although R alone
induced some BMRF1 expression, the addition of Na did not
enhance BMRF1 expression (Fig. 4B). Finally, in the LCL
R-KO line, although transfected R was clearly visible, no sig-
nificant BMRF1 expression was observed in the presence of R
alone or with the combination of R and Na (Fig. 4C). Thus, the
ability of R to induce a lytic EBV infection, as previously
described (46, 68), is clearly cell line dependent. Furthermore,
the synergistic effect of Na and R together also appears to be
modified by either host-cell-dependent or virus-dependent
conditions (such as epigenetic modifications of the viral ge-
nome) that are currently poorly defined.
Na increases the ability of R to activate EBV replication in
293 R-KO cells. The ability of Na to enhance R activation of
lytic gene transcription in at least some cell types (particularly
293 R-KO cells) suggests that the combination of Na and R
may likewise increase the amount of lytic viral replication. To
determine if this increase in early gene transcription results in
an increase in the amount of infectious virus, we harvested the
supernatants of 293 R-KO cells transfected with either vector
DNA, R alone, Na alone, or a combination of R and Na. The
filtered supernatants were than used to infect Raji cells, which
express the EBV receptor at a high level, and the amount of
infectious virus in each 293 cell supernatant was quantitated by
determining the number of GFP-positive Raji cells. As shown
in Fig. 5, 293 R-KO cells transfected with the combination of
R and Na produced fivefold more infectious EBV than cells
transfected with R alone. Thus, the ability of Na to enhance
R-mediated lytic gene expression in this cell type also corre-
lates with increased lytic viral replication.
Na activates Zp in EBV-negative cells. The previous results
suggested that Na is important for the efficient induction of
lytic infection by R in some cell types. In addition, the ability of
Na to enhance R activation of lytic viral genes in some cell
types suggests that either Na enhances BRLF1 transcriptional
function or Na itself is a transcriptional activator. To deter-
mine if Na itself is a transcriptional activator, we performed
reporter gene assays with HeLa cells, using constructs in which
either the BZLF1 (Zp) or BMRF1 (EAp) promoter was posi-
tioned upstream of the CAT gene. The Zp-CAT construct
contains the BZLF1 promoter sequence from 221 to 12,
which has been shown to be sufficient for the induction of Zp
activity by a variety of stimuli (4, 17). Although the expression
of Na had no effect on the activity of the construct driven by
the BMRF1 (EAp) promoter, it increased the activity of the
construct driven by Zp sevenfold (Fig. 6). In contrast, a Zp
construct with a deletion of the Zp sequence 5 of 65 was not
activated by Na. These results indicate that Na specifically
activates Zp and that sequences in Zp located between 65
and 221 are required for this effect.
Na activates Zp through a CRE site. Zp has been extensively
characterized, and a number of different positively acting reg-
ulatory elements have been mapped within the Zp sequences
located between 65 and 221 relative to the transcription
start site (Fig. 7A). Sequences previously shown to be impor-
tant for Zp activation by a variety of different stimuli include a
CRE motif (ZII) (17), which binds CREB, ATF1, ATF2, and
c-Jun (1, 34, 37, 63); a series of ZI sites (5, 16, 17), which bind
MEF2D, Sp1, and Sp3 (22, 35, 36); and ZIII sites, which bind
FIG. 5. Na increases the ability of R to activate EBV replication in
293 R-KO cells. Supernatants from the cells transfected for Fig. 3B
were harvested, and the amounts of infectious virus present were
quantitated as described in Materials and Methods. x axis labels rep-
resent the transfected plasmids and y axis labels represent the numbers
of infectious units per milliliter of supernatant harvested. The data
shown represent the results of two independent experiments.
FIG. 6. Na activates the Z promoter (Zp) in EBV-negative cells.
HeLa cells were transfected with one of the indicated reporter con-
structs (Zp-CAT, 65Zp-CAT, EA-pBS-CAT, or pBS-CAT) in con-
junction with either pRC (vector) or pRC-FLAG-BRRF1 (Na). Cells
were harvested at 48 h posttransfection and CAT assays were per-
formed. The data represent the results of two independent experi-
ments.
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Z and may mediate positive autoregulation (16), although this
point is controversial (29, 31, 68). In addition, several SMAD
binding elements, including one which overlaps the ZII site,
have been implicated in the activation of Zp in response to
transforming growth factor beta (33). To determine if a ZI or
ZII site is required for Na transactivation of Zp, we examined
the ability of Na to activate transcription from wild-type Zp-
CAT versus a Zp-CAT plasmid containing specific mutations
in two ZI sites (Zp-CAT ZIA/ZIB) or a Zp-CAT construct
containing a mutant CRE (ZII) site (Zp-CAT ZII) (Fig. 7A).
Mutation of the ZIA and ZIB sites had no effect on the Na
induction of Zp, whereas mutation of the ZII CRE site com-
pletely eliminated Na’s ability to activate Zp (Fig. 7B). These
results suggest that Na activates Zp through the ZII CRE site.
To determine if a consensus CRE motif is sufficient to me-
diate Na transactivation, we compared the ability of Na to
transactivate a reporter plasmid containing three consensus
CRE sites upstream of a minimal adenovirus E1b promoter
versus a construct containing three copies of a mutant CRE
motif (Fig. 7C). These results indicated that the CRE motif is
sufficient to mediate the Na transactivator effect.
FIG. 7. Na activates Zp through a CRE site. (A) Diagram of the Zp reporter constructs used. The primary elements that positively regulate
Zp are denoted in boxes, with the known transcription factors that bind them represented above. Site-directed mutations in either ZIA and ZIB
or ZII are indicated with an “X.” (B) HeLa cells were transfected with one of the indicated reporter constructs (Zp-CAT, Zp-CAT ZIA/ZIB,
Zp-CAT ZII) in conjunction with either pSG5 (vector) or pRC-FLAG-BRRF1 (Na). Cells were harvested at 48 h posttransfection and CAT
assays were performed. The data represent the results of two independent experiments. (C) HeLa cells were transfected with one of the indicated
reporter constructs [3CRE-CAT or 3CRE(mut)-CAT] in conjunction with either pRC (vector) or pRC-FLAG-BRRF1 (Na). Cells were harvested
at 48 h posttransfection and CAT assays were performed. The data shown represent the results of two independent experiments.
FIG. 8. Na activates c-Jun transactivator function. HeLa cells were
transfected with Gal4-EIB-CAT in conjunction with a vector express-
ing one of the Gal4-fusion proteins (Gal4-ATF1, Gal4-ATF2, Gal4-
CREB, or Gal4–c-Jun) or the control vector expressing Gal4 alone
(Gal4). In addition, either pRC-FLAG-BRRF1 (Na) or pRC (vector)
was also transfected into the cells. Cells were harvested and assayed for
CAT activity at 48 h posttransfection. The data shown represent the
results of two independent experiments.
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Na activates c-Jun transactivator function. The ZII CRE
site of Zp binds the transcription factors CREB, ATF-1,
ATF-2, and c-Jun (1, 34, 37, 63), all of which have been shown
to activate Zp in reporter assays (1, 34, 63). Since Na activates
Zp through the ZII CRE site, we examined whether Na can
activate CREB, ATF-1, ATF-2, or c-Jun fusion proteins linked
to the Gal4 DNA binding domain. The abilities of ATF-1,
ATF-2, CREB-1, and c-JUN Gal4 fusion proteins to activate a
reporter plasmid containing five copies of the Gal4 DNA bind-
ing site upstream of the CAT gene, in the presence or absence
of cotransfected Na, were examined in HeLa cells. As seen in
Fig. 8, Na specifically activated the c-Jun transcriptional func-
tion, while it did not significantly affect the function of ATF-1,
ATF-2, or CREB-1. Since the DNA binding activity in these
experiments was mediated through the Gal4 DNA binding
domain of the fusion proteins, these results suggest that Na
activates promoters by enhancing the c-Jun transcriptional
function.
Na increases levels of hyperphosphorylated c-Jun. Efficient
c-Jun transcriptional functioning requires the phosphorylation
of serines 63 and 73 in c-Jun by JNK (12, 25, 30). c-Jun
phosphorylated at Ser63 and Ser73 is more stable (41) and has
an enhanced ability to transactivate target promoters (43). We
therefore determined if Na expression affects c-Jun phosphor-
ylation. The c-Jun phosphorylation status was monitored by
using an antibody specific for c-Jun phosphorylated at Ser73
versus an antibody that recognizes total c-Jun. Although HeLa
cells transfected with c-Jun alone displayed a low level of basal
c-Jun phosphorylation (Fig. 9, P-c-Jun, lower arrow), the pres-
ence of Na significantly increased the amount of heavily phos-
phorylated c-Jun (P-c-Jun, upper arrow). The specificity of the
phospho-c-Jun antibody for phosphorylated c-Jun was verified
by using blocking peptides specific for phospho-c-Jun (data not
shown). The slightly increased level of total c-Jun in the pres-
ence of Na possibly reflects the increased stability of c-Jun in
response to phosphorylation (41).
DISCUSSION
The switch from a latent to lytic infection during the EBV
life cycle is a tightly regulated process in which the expression
of the IE genes Z and R plays a pivotal role in initiating the
transition. The expression of either IE protein results in ex-
pression of the other, and this ability of Z or R to turn on the
promoter of the other corresponding IE gene is critical for the
efficient induction of lytic infections (2, 14, 68). The IE region
of EBV expresses a gene within the intronic sequence of R,
designated Na or BRRF1, that is transcribed with early kinetics
in response to Z (53). Na encodes a 34-kDa nuclear protein
whose function in the viral life cycle was previously unknown.
In this report, we demonstrated that Na functions as a viral
transactivator that enhances the ability of R to disrupt latency
in a 293 cell line carrying a recombinant EBV defective for
expression of both R and Na. The expression of R in conjunc-
tion with Na results in increased levels of viral lytic genes
compared to expression of R alone. In addition, the presence
of Na also results in a fivefold increase in the amount of
infectious virus produced after an R-induced lytic infection.
The ability of Na to enhance R-induced lytic infection in 293
cells appears to be at least partially mediated through Na’s
ability to activate the Z promoter. Increased levels of Z were
observed in the presence of R and Na in combination com-
pared to R alone, suggesting that the presence of Na increased
the transcription of Z from the endogenous genome. Although
Na alone could not activate Z transcription in the context of
the intact viral genome, Na alone was able to specifically trans-
activate a Zp reporter construct in EBV-negative HeLa cells.
The ability of Na to activate Zp required the CRE (ZII) site,
and the consensus CRE site was shown to be sufficient to
confer Na responsiveness to a heterologous promoter. These
data suggest that the CRE element is the primary target of
Na-induced transactivation.
The Zp CRE site binds ATF-1, ATF-2, c-Jun, and CREB (1,
34, 37, 63). Of these, the phospho-ATF-2/phospho-c-Jun het-
erodimer may represent the predominant complex responsible
for R activation of the Zp CRE site (1). We showed here that
Na specifically activates the transcriptional function of c-Jun
while not affecting the transcriptional function of ATF-1,
ATF-2, or CREB-1. Thus, Na likely activates Zp by enhancing
c-Jun transcriptional functioning. This activation of c-Jun by
Na appears to be independent of changes in c-Jun DNA bind-
ing, as the activity of a Gal4–c-Jun fusion protein (in which
DNA binding was mediated by Gal4) was also activated by Na.
Since the phosphorylation of c-Jun residues Ser63 and Ser73 is
required for efficient c-Jun transcriptional functioning, we ex-
amined the effect of Na on c-Jun phosphorylation. We found
that Na increases the levels of a hyperphosphorylated form of
c-Jun, suggesting that Na activates c-Jun by increasing its phos-
phorylation. Since the phosphorylation of c-Jun residues Ser63
and Ser73 is commonly mediated by JNK (12), these results
indicate that Na may activate JNK. However, the exact mech-
anism by which Na modulates c-Jun phosphorylation has not
yet been determined. Given that the ZII element is responsive
to transforming growth factor beta and binds SMADs (33), it is
possible that Na modulates SMADs in addition to c-Jun in
order to transactivate Zp through ZII; this possibility remains
to be examined.
An interesting result of these studies was the finding that
while Na efficiently activates Zp in reporter gene assays, it does
not by itself activate BZLF1 transcription from the intact viral
genome in cells that are latently infected with EBV. Instead,
FIG. 9. Na increases levels of hyperphosphorylated c-Jun. HeLa
cells were transfected with pRC (vector), pRC-FLAG-BRRF1 (Na),
pCMV-c-Jun (c-Jun), or pRC-FLAG-BRRF1 plus pCMV-c-Jun
(Nac-Jun). Harvesting occurred at 48 h posttransfection, and 35 g
of protein was immunoblotted for c-Jun phosphorylated on Ser73
(P-c-Jun) (upper panel) or total c-Jun (lower panel).
VOL. 78, 2004 EBV BRRF1 PROTEIN ENHANCES LYTIC INFECTION 4989
Na primarily enhances the ability of R to activate BZLF1
transcription from the endogenous viral genome in certain
settings. We speculate that the Na transactivator function,
which is mediated through the c-Jun transcription factor, is
inhibited by the epigenetic modification of the EBV genome in
latently infected cells, which includes DNA methylation of the
BZLF1 promoter region as well as an inactive (deacetylated)
state of the chromatin surrounding Zp (22). R-mediated acti-
vation of Zp is also thought to be mediated through cellular
factors binding to the CRE motif, suggesting that the relative
inability of R to efficiently activate Z transcription in certain
cell types (such as lymphoblastoid lines) may likewise reflect
the effect of inhibitory epigenetic modifications of the viral
genome. Notably, MEF2D binding to the ZI motifs in Zp has
been previously shown to modulate the histone acetylation of
Zp in the context of the intact viral genome (22). Zp reporter
constructs may not accurately mimic the state of Zp in the
context of the intact viral genome, particularly in regard to the
effects of chromatin structure and DNA methylation.
The relative contributions of the various cellular transcrip-
tion factors (ATF-1, CREB-1, ATF-2, and c-Jun) which acti-
vate Zp transcription through the CRE motif to reporter gene
assays are not currently understood with regard to their im-
portance for inducing BZLF1 transcription in the context of
the intact viral genome. It is possible that the state of Zp
methylation and/or chromatin acetylation differentially influ-
ences the ability of these cellular factors to activate Zp tran-
scription from the endogenous viral genome. In addition, cell-
type-dependent factors may influence the relative importance
of each transcription factor in activating BZLF1 transcription
from the viral genome. In situations in which the combination
of ATF-2 and c-Jun is sufficient for activating BZLF1 tran-
scription from the endogenous viral genome, the synergistic
effect of R and Na together may reflect the ability of R to
activate p38 kinase (which phosphorylates and activates
ATF-2) combined with the ability of Na to enhance the level of
heavily phosphorylated c-Jun. In cell types in which R and Na
together do not efficiently induce BZLF1 transcription (such
as lymphoblastoid cells), it remains possible that activated
CREB-1 and/or ATF-1 could efficiently induce BZLF1 tran-
scription from the intact viral genome. Our finding that Na
enhances R-induced lytic infections in certain epithelial lines,
but not in two B-cell lines, suggests that c-Jun activation may
be more important for BZLF1 transcription in some cell types
than in others. Hence, Na may be more important for viral
replication in some cells and/or tissues than in others.
Our results suggest (but do not prove) that Na may activate
JNK. Alternatively, Na may inhibit the dephosphorylation of,
or degradation of, phosphorylated c-Jun. JNK, along with p38,
is a member of the SAPK family, and both of these kinases
activate c-Jun and/or ATF-2 in response to cellular stress (12,
23, 47, 62). SAPK activation is a common theme among her-
pesviruses, with herpes simplex virus type 1, CMV, Kaposi’s
sarcoma-associated herpesvirus, and EBV all inducing p38
and/or JNK during infection (1, 3, 26, 40, 66, 67). Cross-linking
of the B-cell receptor, an event that is thought to be a physi-
ologically important stimulus for the in vivo reactivation of
EBV (57), also results in JNK and p38 activation (56). Inhibi-
tion of the SAPKs results in a reduced efficiency of lytic infec-
tion for alpha-, beta-, and gammaherpesviruses (1, 27, 40),
suggesting that viruses have evolved to utilize the cellular
SAPK pathway to both trigger and facilitate lytic infection.
Members of our lab have previously demonstrated that both Z
and R activate the SAPKs and that R-mediated SAPK induc-
tion is required for the efficient activation of Zp by R (1). The
ability of yet another lytic EBV protein, Na, to increase the
levels of hyperphosphorylated c-Jun suggests that activated
c-Jun is indeed important for efficient lytic EBV infection and
that there may be multiple, redundant mechanisms encoded by
the virus to ensure that this activation occurs.
In summary, we demonstrated here for the first time a func-
tion of the early Na gene product of EBV. Na enhances the
ability of R to induce lytic infection by cooperating with R to
activate the Z promoter, and this effect of Na appears to be
more important in some cell types than in others. Whether
there are additional Na-responsive viral promoters in the EBV
genome (in addition to Zp) remains an open question. Our
results suggest the existence of a previously unrecognized au-
tostimulatory pathway for lytic EBV induction in which an
initial activating stimulus (e.g., differentiation) which induces a
low-level activation of either Zp or Rp would subsequently be
amplified by the ability of Na to further induce Zp activation.
Future insights into the mechanism of the Na function should
allow a more thorough understanding of lytic cycle regulation,
and given the cell type dependence of Na activity, could shed
light on the cellular and viral characteristics that influence viral
permissiveness.
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